Bibliography
- Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell 2012;148(5):852-71
- Vetere A, Choudhary A, Burns SM, et al. Targeting the pancreatic β-cell to treat diabetes. Nat Rev Drug Discov 2014;13(4):278-89
- Shen W, Tremblay MS, Deshmukh VA, et al. Small-molecule inducer of β cell proliferation identified by high-throughput screening. J Am Chem Soc 2013;135(5):1669-72
- Annes JP, Ryu JH, Lam K, et al. Adenosine kinase inhibition selectively promotes rodent and porcine islet β-cell replication. Proc Natl Acad Sci USA 2012;109(10):3915-20
- Andersson O, Adams BA, Yoo D, et al. Adenosine signaling promotes regeneration of pancreatic β cells in vivo. Cell Metab 2012;15(6):885-94
- Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010;140(6):900-17
- Mussmann R, Geese M, Harder F, et al. Inhibition of GSK3 promotes replication and survival of pancreatic beta cells. J Biol Chem 2007;282(16):12030-7
- Burant CF, Viswanathan P, Marcinak J, et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2012;379(9824):1403-11
- Maedler K, Sergeev P, Ris F, et al. Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002;110(6):851-60
- Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356(15):1517-26
- Paquot N, Castillo MJ, Lefebvre PJ, et al. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 2000;85(3):1316-19
- Kitada M, Kume S, Kanasaki K, et al. Sirtuins as possible drug targets in type 2 diabetes. Curr Drug Targets 2013;14(6):622-36
- de Kreutzenberg SV, Ceolotto G, Papparella I, et al. Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: potential biochemical mechanisms. Diabetes 2010;59(4):1006-15
- Kang W, Hong HJ, Guan J, et al. Resveratrol improves insulin signaling in a tissue-specific manner under insulin-resistant conditions only: in vitro and in vivo experiments in rodents. Metabolism 2012;61(3):424-33
- Morris AP, Voight BF, Teslovich TM, et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet 2012;44(9):981-90
- Caffrey MK. Study on protective gene mutations for T2DM appears to have strong impliactions for drug development. Evidence-Based Diabetes Management 2014;20:SP4-102
- Flannick J, Thorleifsson G, Beer NL, et al. Loss-of-function mutations in SLC30A8 protect against type 2 diabetes. Nat genet 2014;46(4):357-63
- Gupta S, Jain A, Chakraborty M, et al. Oral delivery of therapeutic proteins and peptides: a review on recent developments. Drug deliv 2013;20(6):237-46